Picado César
University of Barcelona, Servei de Pneumologia i Allèrgia Respiratoria, Hospital Clínic, c/Villarroel 170, 08036 Barcelona, Spain.
Expert Opin Pharmacother. 2006 Oct;7(14):1989-2001. doi: 10.1517/14656566.7.14.1989.
Rupatadine is a once-daily, non-sedating, selective and long-acting new drug with a strong antagonist activity towards both histamine H(1) receptors and platelet-activating factor receptors. The use of rupatadine is indicated in adult and adolescent patients (> 12 years of age) suffering from intermittent and persistent allergic rhinitis and chronic idiopathic urticaria. In the treatment of these diseases, rupatadine is at least as effective as ebastine, cetirizine, loratadine and desloratadine. A very good safety profile of rupatadine has been evidenced in various studies, including a long-term (1-year) safety study. Rupatadine does not present drug-drug interactions with azithromycin, fluoxetine and lorazepam, but should not be administered concomitantly with known CYP3A4 inhibitors.
卢帕他定是一种每日服用一次、无镇静作用、具有选择性和长效性的新药，对组胺H(1)受体和血小板活化因子受体均具有强大的拮抗活性。卢帕他定适用于患有间歇性和持续性过敏性鼻炎以及慢性特发性荨麻疹的成人和青少年患者（年龄大于12岁）。在治疗这些疾病方面，卢帕他定的疗效至少与依巴斯汀、西替利嗪、氯雷他定和地氯雷他定相当。各种研究均已证明卢帕他定具有非常良好的安全性，包括一项为期1年的长期安全性研究。卢帕他定与阿奇霉素、氟西汀和劳拉西泮不存在药物相互作用，但不应与已知的CYP3A4抑制剂同时给药。
